COMMUNIQUÉS West-GlobeNewswire
-
QuantX Biosciences Closes Oversubscribed $85M Series B Financing
09/02/2026 -
Trained Therapeutix Discovery Appoints Distinguished Industry Leaders to its Board of Directors
09/02/2026 -
Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy
09/02/2026 -
Bionano Announces Bionano Symposium 2026: Global Experts Showcase Advances and Innovation in Optical Genome Mapping
09/02/2026 -
Argá Medtech Reports 94% Lesion Durability and Strong Safety Profile in First-in-Human BURST-AF Trial of Single-Catheter PFA System
09/02/2026 -
Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical
09/02/2026 -
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/02/2026 -
The Oxford-Harrington Rare Disease Centre Advances Discovery of Therapies for Friedreich’s Ataxia (FA)
09/02/2026 -
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/02/2026 -
Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial
09/02/2026 -
ProQR Announces Planned Changes to Board Composition
09/02/2026 -
Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium
09/02/2026 -
SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)
09/02/2026 -
XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
09/02/2026 -
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
09/02/2026 -
ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in Extensive Stage Small Cell Lung Cancer
09/02/2026 -
Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
09/02/2026 -
Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
09/02/2026 -
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
09/02/2026
Pages